

Company name: KAHR Medical Website: <https://kahrbio.com/>
CEO name: Yaron Pereg

CATEGORY: Biotech/Pharma SESSIONS: Evolving trends in Cancer Therapeutics.

o Executive Summary / Investment Rational KAHR is a clinical-stage oncology company developing multi-functional dual-targeting fusion proteins that activate the innate and adaptive immune systems simultaneously to bolster anti-tumor activity in difficult to treat cancer patients. Our lead product, DSP107, is being tested in phase I/II studies under clinical collaboration with Roche. Topline efficacy results are expected during 2024. The company raised to date approx. \$130M.

o Core Technology We employ our Multi-Functional Immuno-Recruitment (MIRP) platform to design product candidates that have two distinct targeting domains. Our products target key receptors expressed on tumor and immune cells. The resulting fusion protein is tumor specific and capable of both unblocking immunosuppressive mechanisms while simultaneously activating and propagating key immune cells. This synergistic and tumor-localized activity ensures enhanced efficacy and safety.

o Product Profile/Pipeline DSP107 blocks CD47 on cancer cells and engages 4-1BB expressing cytotoxic T-cell to the tumor microenvironment. Phase I data demonstrated objective responses in MSS colorectal cancer patients, a cold tumor that is non-responsive to immunotherapy. Importantly, DSP107 has demonstrated excellent safety profile, no binding to RBCs and lack of hematological or hepato-toxicities differentiating it from other CD47 and 4-1BB agents.

o Business Strategy Our strategy is to be the first company to develop (i) a CD47 inhibitor approved for the treatment of solid tumors and (ii) an approved 4-1BB engager. If we are successful, we will be able to access the multibillion-dollar colorectal cancer market as early as 2026, with additional indications creating additional revenue opportunities within a few years afterwards. o What's Next? We plan to expand the clinical development of DSP107 and assess its potential

in additional solid and hematological malignancies. In preparation for a potential future phase III study, we plan to scale-up its manufacturing processes. In addition, we will advance the preclinical development of other product candidates including DSP502 (targeting PVRxPD-L1) and DSP216 (targeting HLA-GxCD47).